Marianne Murphy

Marianne Murphy holds a PhD in immunology and has extensive experience in T cell and cytokine biology, monoclonal antibody technologies and project management. She played a key role in the discovery and validation of numerous clinical targets and was one of the first to produce neutralizing monoclonal antibodies and an immunoassay to human TNF, the target for Remicade and Enbrel. She has academic experience at Wistar Institute, University of Pennsylvania (Philadelphia, PA, USA) and University of California, San Francisco (CA, USA) and over 18 years Biotech experience at Human Genome Sciences (Rockville, MD, USA), Celltech (Slough, UK) and RiboVax Biotechnologies (Geneva, Switzerland).